Elevidys

Sarepta enjoys early sales ramp for DMD gene therapy, maintains confidence in label expansion
Sarepta enjoys early sales ramp for DMD gene therapy, maintains confidence in label expansion
Fierce Pharma
Sarepta Therapeutics
DMD
Duchenne Muscular Dystrophy
Elevidys
gene therapy
Flag link:
Sarepta gene therapy for Duchenne misses main goal of key study
Sarepta gene therapy for Duchenne misses main goal of key study
BioPharma Dive
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
clinical trials
FDA
Elevidys
Flag link:
6 Drugs Approved Despite Failed Trials or Minimal Data
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Flag link:
Sarepta offers early look at closely watched gene therapy launch
Sarepta offers early look at closely watched gene therapy launch
BioPharma Dive
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
Elevidys
drug launches
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
Flag link:
Sarepta prices Duchenne gene therapy at $3.2M
Sarepta prices Duchenne gene therapy at $3.2M
BioPharma Dive
Sarepta Therapeutics
drug pricing
DMD
Duchenne Muscular Dystrophy
Elevidys
Flag link:
FDA Approves Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy
FDA Approves Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy
BioSpace
Sarepta Therapeutics
DMD
Duchenne Muscular Dystrophy
FDA
Elevidys
gene therapy
Flag link: